Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Sergernne York et al.|The Lancet Oncology|2012Cited by 411
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylateElias Jabbour, Jörge E. Cortes, Hagop M. Kantarjian et al.|Leukemia|2006Cited by 387
Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.H. Kantarjian, AB Deisseroth, Moshe Talpaz et al.|Journal of Clinical Oncology|1992Cited by 65